Transforming the treatment of cognitive impairment
The mental healthcare system is in desperate need of innovation.
By combining scientific innovation with deep domain expertise, we are determined to deliver ground-breaking treatment for those suffering with a debilitating disorder effecting millions worldwide.
An atai Life Sciences company
Recognify Life Sciences is a biotech company leveraging a Phase 2 ready asset to treat Cognitive Impairment associated with Schizophrenia (CIAS).
“Cognitive deficits are the most common, and often the first, symptom to present when a patient is suffering from a central nervous system disease or disorder. The impact can be profound not only to the patient but also their caregivers. Novel treatments to support cognitive function, particularly in fragile populations, are in dire need and would greatly improve patient quality of life and reduce societal burdens ”
— Matt Pando, CEO & President, Recognify Life Sciences
Want to learn more? Sign up for the #InsightNetwork for important updates.
Lets bridge the gap between what the mental healthcare system can provide and what people really need.